Fecal microbiota transplantation treatment of autoimmune-mediated type 1 diabetes: A systematic review

Shuo Zhang; Shuo Zhang; Feiying Deng; Feiying Deng; Jingxian Chen; Jingxian Chen; Fengwu Chen; Fengwu Chen; Zezhen Wu; Zezhen Wu; Liping Li; Kaijian Hou; Kaijian Hou

doi:10.3389/fcimb.2022.1075201

Frontiers in Cellular and Infection Microbiology (Dec 2022)

Fecal microbiota transplantation treatment of autoimmune-mediated type 1 diabetes: A systematic review

Shuo Zhang,
Shuo Zhang,
Feiying Deng,
Feiying Deng,
Jingxian Chen,
Jingxian Chen,
Fengwu Chen,
Fengwu Chen,
Zezhen Wu,
Zezhen Wu,
Liping Li,
Kaijian Hou,
Kaijian Hou

Affiliations

Shuo Zhang: Shantou University Medical College, Shantou, China
Shuo Zhang: Department of Endocrine and Metabolic Diseases, The First Affiliated Hospital of Shantou University Medical College, Shantou, China
Feiying Deng: Shantou University Medical College, Shantou, China
Feiying Deng: Department of Endocrine and Metabolic Diseases, The First Affiliated Hospital of Shantou University Medical College, Shantou, China
Jingxian Chen: Department of Endocrine and Metabolic Diseases, Longhu People’s Hospital, Shantou, China
Jingxian Chen: School of Public Health, Shantou University, Shantou, China
Fengwu Chen: Department of Endocrine and Metabolic Diseases, The First Affiliated Hospital of Shantou University Medical College, Shantou, China
Fengwu Chen: Department of Endocrine and Metabolic Diseases, Longhu People’s Hospital, Shantou, China
Zezhen Wu: Shantou University Medical College, Shantou, China
Zezhen Wu: Department of Endocrine and Metabolic Diseases, The First Affiliated Hospital of Shantou University Medical College, Shantou, China
Liping Li: School of Public Health, Shantou University, Shantou, China
Kaijian Hou: Department of Endocrine and Metabolic Diseases, Longhu People’s Hospital, Shantou, China
Kaijian Hou: School of Public Health, Shantou University, Shantou, China

DOI: https://doi.org/10.3389/fcimb.2022.1075201
Journal volume & issue: Vol. 12

Abstract

Read online

There is a strong link between fecal microbiota and the development of type 1 diabetes. As an emerging therapeutic modality, fecal microbiota transplantation has been shown to be safe and effective in the treatment of many intestinal and extraintestinal diseases. Various studies have found that fecal microbiota transplantation can treat diseases by correcting patients’ immune disorders. Besides, many studies have found that fecal microbiota transplantation can improve glycemic control and insulin resistance in diabetic patients. Therefore, this paper reviews the mechanism of action of fecal microbiota transplantation on autoimmune-mediated T1DM and the current research progress, feasibility, and issues that need to be addressed in the future development of fecal microbiota transplantation in the treatment of autoimmune-mediated T1DM.

Published in Frontiers in Cellular and Infection Microbiology

ISSN: 2235-2988 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Science: Microbiology
Website: http://www.frontiersin.org/Cellular-and-Infection-Microbiology

About the journal

Abstract

Keywords